Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
TB-500
Also known as: Thymosin Beta-4, TB4, Timbetasin
TB-500 is a synthetic fraction of thymosin beta-4, a naturally occurring 43-amino-acid peptide involved in cell migration and tissue repair. It plays a key role in wound healing, inflammation reduction, and cellular differentiation. Research interest centers on its ability to promote recovery from injuries across multiple tissue types.
Risk Level
Low RiskDifficulty
Beginner| CAS Number | 77591-33-4 |
| Molecular Formula | C212H350N56O78S |
| Class | Peptide |
| Category | Well-Known Peptides |
Mechanism of Action
Thymosin beta-4 sequesters G-actin monomers, regulating actin polymerization which is essential for cell motility and migration to injury sites. It upregulates anti-inflammatory cytokines and promotes angiogenesis by stimulating endothelial cell migration. TB-500 also activates cardiac progenitor cells and has demonstrated cardioprotective effects in ischemia models.
Dosing Research
Common research protocols use 2-2.5 mg administered subcutaneously twice per week during a loading phase of 4-6 weeks, followed by a maintenance dose of 2 mg every two weeks. Total weekly loading doses typically range from 4-5 mg.
Side Effects & Risks
Side effects are generally mild and may include headache, lethargy, and localized injection site irritation. There is a theoretical concern about promoting growth of existing cancers due to angiogenic properties, though direct evidence is limited. Temporary head rush shortly after injection has been reported.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Liraglutide
PeptideLiraglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). It was the first GLP-1 agonist approved specifically for weight management. While effective, it has been largely superseded by semaglutide and tirzepatide in terms of weight loss efficacy.
PT-141
PeptidePT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through the melanocortin system to increase sexual desire rather than just facilitating erection mechanics. It is the only FDA-approved on-demand treatment targeting central sexual arousal pathways.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.